Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Oct west coast 2025

    1 min read

    OCT West Coast


    Meet Veristat at OCT West Coast 2025

    Veristat is excited to participate in the 17th Annual Outsourcing in Clinical Trials (OCT) West Coast, taking place February 11-12, 2025, at the Hyatt Regency San Francisco Airport in Burlingame, California.

    This premier event brings together industry leaders to discuss and explore the latest strategies in clinical outsourcing, offering an invaluable opportunity to share insights, tackle challenges, and optimize partnerships with third-party suppliers.

    Veristat has been a trusted source of intellectual leadership and scientific-minded guidance in clinical development to guide critical decision-making. We provide strategic level thinking to help sponsors optimize their clinical development and regulatory submission strategies for timely results.

    Our team looks forward to engaging in discussions and showcasing how Veristat’s flexible full-service models help sponsors accelerate patient access to high quality therapies globally.

    Veristat Attendees: 

    Kevin Keenan -  Senior Business Development Director

    Conference Details: 

    Date: February 11-12, 2025
    Location: Hyatt Regency San Francisco Airport, Burlingame, California

    Schedule a Meeting:  

    Connect with Veristat experts to learn how we can help you accomplish more, more effectively and with less worry. Fill out the form to schedule a meeting with our team.

    Learn more about the conference

     

     

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...